Cargando…
Connexin 30 deficiency attenuates A2 astrocyte responses and induces severe neurodegeneration in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride Parkinson’s disease animal model
BACKGROUND: The first pathology observed in Parkinson’s disease (PD) is ‘dying back’ of striatal dopaminergic (DA) terminals. Connexin (Cx)30, an astrocytic gap junction protein, is upregulated in the striatum in PD, but its roles in neurodegeneration remain elusive. We investigated Cx30 function in...
Autores principales: | Fujita, Atsushi, Yamaguchi, Hiroo, Yamasaki, Ryo, Cui, Yiwen, Matsuoka, Yuta, Yamada, Ken-ichi, Kira, Jun-ichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090688/ https://www.ncbi.nlm.nih.gov/pubmed/30103794 http://dx.doi.org/10.1186/s12974-018-1251-0 |
Ejemplares similares
-
Overexpression of Parkin Ameliorates Dopaminergic Neurodegeneration Induced by 1- Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine in Mice
por: Bian, Minjuan, et al.
Publicado: (2012) -
e-Cadherin in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Parkinson Disease
por: Cataldi, Samuela, et al.
Publicado: (2016) -
Hydrogen in Drinking Water Reduces Dopaminergic Neuronal Loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Mouse Model of Parkinson's Disease
por: Fujita, Kyota, et al.
Publicado: (2009) -
Anti-parkinsonian effects of octacosanol in 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine-treated mice☆
por: Wang, Tao, et al.
Publicado: (2012) -
Acute Morphine Treatments Alleviate Tremor in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Treated Monkeys
por: Yan, Ting, et al.
Publicado: (2014)